Skip to main content

Posts

Showing posts from January, 2021

Orthodontics : A Study in Oral Healthcare System

  Oral healthcare is one of the prominent concerns within the global healthcare system. For instance, according to a study conducted by Lancet, titled, “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017,” in 2018, oral diseases impacted 3.5 billion individuals globally. Moreover, more than 530 million children globally were impacted by dental caries of permanent teeth. Furthermore, the rising prevalence of oral health diseases has also furthered the spread of non-communicable diseases. One of the major concerns within the oral healthcare system is the oro-dental trauma caused by the misalignment or malocclusion of teeth. According to a study conducted by National Center for Biotechnology Information (NCBI), titled, “World traumatic dental injury prevalence and incidence, a meta-analysis- One billion living peop

CAR T-Cell Therapy - Treatment of Various Hematological Malignancies

  CAR T-cell (Chimeric Antigen Receptor T-cell) therapy is used predominantly in the treatment of various hematological malignancies (HMs), such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma), and multiple myeloma (MM). HMs are blood cancers caused due to the uncontrolled growth of lymphoid and hematopoietic tissues (bone marrow). HMs are clinically and biologically heterogeneous disorders responsible for nearly 6.5% of all cancers across the globe, around 9.0% of cancers in the U.S. and Europe collectively. According to the estimates provided by Global Cancer Observatory (Globocan), an international agency for research on cancer, the total number of prevalent cases of hematologic malignancies in the world was 2,903,711 in 2018. The U.S. contributed around 15% of global prevalent cases of hematologic malignancies, and China contributed around 17% of total cases in 201